Results 201 to 210 of about 24,647,321 (271)
Plasma Proteome Reflects Tissue Damage and Clinical Manifestations in Patients With Inflammatory Myopathies
Arthritis &Rheumatology, EarlyView.Objective
Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins.Yue‐Bei Luo, Josefin Kenrick, Angeles S. Galindo‐Feria, Antonella Notarnicola, Ana Daniela Ulloa Navas, Irene Peralta‐Garcia, Orane Demuynck, Andrea Kemp, Valérie Leclair, Karin Lodin, Eveline Van Gompel, Lara Dani, Fabricio Espinosa‐Ortega, Maryam Dastmalchi, Leonid Padyukov, Charlotta Preger, María Bueno Álvez, Mathias Uhlén, Peter Nilsson, Fredrik Edfors, Lina‐Marcela Diaz‐Gallo, Elisa Pin, Ingrid E. Lundberg, Begum Horuluoglu +23 morewiley +1 more sourceThe synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis
Arthritis &Rheumatology, Accepted Article.Objective
Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming +15 morewiley +1 more sourceHigher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.
Arthritis &Rheumatology, Accepted Article.Background
Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods
We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C).Namrata Singh, A. Jerrod Anzalone, Holland Stevenson, Londyn Robinson, Lesley E. Jackson, Sandra E. Safo, Zachary Butzin‐Dozier, Kaleb Michaud, Maria I. Danila, Jasvinder A. Singh, Rena C. Patel, on behalf of the National Clinical Cohort Collaborative (N3C) Consortium +11 morewiley +1 more sourceInitial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis
Arthritis &Rheumatology, Accepted Article.Objective
Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods
We analysed treatment‐naïve SSc‐PAH patients in EUSTAR (2000–2021) fulfilling the 2022 haemodynamic definition.Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón‐Aznar, Marie‐Elise Truchetet, Alessandro Giollo, Alexandra Balbir‐Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C. Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K. Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller‐Ladner, Marco Matucci‐Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna‐Maria Hoffmann‐Vold, on behalf of the EUSTAR collaborators +30 morewiley +1 more sourceSema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis
Arthritis &Rheumatology, Accepted Article.Objective
We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods
Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=Jaime Marty, Sara Martinez‐Ramos, Carlos Rafael‐Vidal, Beatriz Malvar‐Fernández, Tiago Carvalheiro, Ralph G. Tieland, Ines Ramos, Wiola Marut, Ana Pinheiro‐Lopes, Ana Argibay, Brenda Maure, Caritina Vázquez‐Triñanes, Nair Pérez Gómez, David Fernández‐Fernández, Sandra Vila, Coral Mouriño, Rogier M Thurlings, Arjan van Caam, Alberto Rivera, José María Pego‐Reigosa, Timothy R. Radstake, Samuel Garcia +21 morewiley +1 more sourceSustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic‐Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double‐Blind, Placebo‐Controlled APEX Study
Arthritis &Rheumatology, Accepted Article.Objective
In APEX, guselkumab, which binds to the IL‐23p19 subunit and CD64 on IL‐23‐producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein. Methods
The APEX modified full analysis set included 1020 biologic‐Christopher T. Ritchlin, Philip J. Mease, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde +12 morewiley +1 more source